MedTrace Logo

Digitalized Surveillance Management for Liver Cancer Risk Population in Improving Eearly Diagnosis Efficancy in Chinese Population (dSEARCH)

NCT05870969 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 20000

Last updated 2023-05-23

No results posted yet for this study

Summary

The goal of this study is to evaluate whether the standardized liver cancer risk stratification management can effectively improve the early diagnosis rate of liver cancer in the targeted risk population in China.

Conditions

  • Carcinoma, Hepatocellular
  • Hepatitis C, Chronic
  • Hepatitis B, Chronic
  • Cirrhosis, Liver
  • Non-Alcoholic Fatty Liver Disease

Interventions

BEHAVIORAL

Liver cancer surveillance every 3 months

Follow up every 3 months for liver cancer surveillance, including but not limited to serum AFP test and ultrasound exam

BEHAVIORAL

Liver cancer surveillance every 6 months

Follow up every 6 months for liver cancer surveillance, including but not limited to serum AFP test and ultrasound exam

BEHAVIORAL

Liver cancer surveillance annually

Follow up annually for liver cancer surveillance, including but not limited to serum AFP test and ultrasound exam

Sponsors & Collaborators

  • Ruijin Hospital

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-03-01
Primary Completion
2028-03-31
Completion
2028-03-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05870969 on ClinicalTrials.gov